NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Del Ben, Maria ^a   Polimeni, Licia ^a   Carnevale, Roberto ^a   Bartimoccia, Simona ^a   Nocella, Cristina ^a   Baratta, Francesco ^a   Loffredo, Lorenzo ^a   Pignatelli, Pasquale ^a   Violi, Francesco ^a   Angelico, Francesco ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

8 iso PGF2 ; Metabolic syndrome; Non alcoholic fatty liver; Oxidative stress; sNOX2 dp

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADIPONECTIN; ALANINE AMINOTRANSFERASE; CYTOKERATIN 18; INSULIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; 8-EPI-PROSTAGLANDIN F2ALPHA; BIOLOGICAL MARKER; CYBB PROTEIN, HUMAN; MEMBRANE PROTEIN; PROSTAGLANDIN F2 ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; ENZYME BLOOD LEVEL; FATTY LIVER; FEMALE; HOMEOSTASIS MODEL OF INSULIN RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PREDICTION; PROTEIN URINE LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; URINE;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS; DINOPROST; FEMALE; HUMANS; LINEAR MODELS; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; NADPH OXIDASE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX;

EID: 84899994163     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-81     Document Type: Article

References (38)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231. 10.1056/NEJMra011775, 11961152.
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for non-alcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
3. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non alcoholic fatty liver disease: an hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003, 18:588-594. 10.1046/j.1440-1746.2003.02958.x, 12702052.
4. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
5. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG I, Zalunardo B, Lirussi F, Alessandri C, Violi F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005, 90:1578-1582. 10.1210/jc.2004-1024, 15598693.
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350. 10.1056/NEJMra0912063, 20879883.
7. Del Ben M, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med 2012, 7(Suppl 3):S291-S296.
8. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006, 12:555-558. 10.1016/j.molmed.2006.10.001, 17049925.
9. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002, 16:663-678. 10.1053/bega.2002.0333, 12406438.
10. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846. 10.1002/hep.24001, 21038418.
11. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. Aliment Pharmacol Ther 2012, 36:815-823.
12. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR NASHCRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New Engl J Med 2010, 362:1675-1685. 10.1056/NEJMoa0907929, 2928471, 20427778.
13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Michael C, Arun Sanyal J. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023. 10.1002/hep.25762, 22488764.
14. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1497-1502. 10.1111/j.1572-0241.2004.30159.x, 15307867.
15. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, Musabak U, Erbil MK, Karaeren N, Dagalp K. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:850-855. 10.1111/j.1572-0241.2005.41500.x, 15784031.
16. Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2010, 43:815-821. 10.1016/j.clinbiochem.2010.04.003, 20398645.
17. Nobili V, Parola M, Alisi A, Marra F, Piemonte F, Mombello C, Sutti S, Povero D, Maina V, Novo E, Albano E. Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. Intern J Molec Med 2010, 26:471-476.
18. Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, Yotsumoto K, Sakurai K, Iwashita H, Hirano G, Ueda SI, Yokoyama K, Morihara D, Nishizawa S, Anan A, Takeyama Y, Sakamoto M, Shakado S, Sakisaka S. Levels of the oxidative stress marker g-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Intern Med Res 2012, 40:924-933.
19. Pirgon O, Bilgin H, Kurku H, Cekmez F, Dündar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2013, 5:33-39. 10.4274/Jcrpe.825, 3628390, 23367495.
20. Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T. For the lido study group: blood oxidative stress markers are unreliable markers of hepatic steatosis. Alim Pharmacol Ther 2006, 23:91-99.
21. Il'yasova D, Scarbrough P, Spasojevic I. Urinary biomarkers of oxidative status. Clin Chim Acta 2012, 413:1446-1453. 10.1016/j.cca.2012.06.012, 3424057, 22683781.
22. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004, 18:1791-1800. 10.1096/fj.04-2330rev, 15576482.
23. Praticò D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 2008, 201:8-16. 10.1016/j.atherosclerosis.2008.04.037, 18514200.
24. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006, 8:691-728. 10.1089/ars.2006.8.691, 16771662.
25. Cangemi R, Angelico F, Loffredo L, Del Ben M, Pignatelli P, Martini A, Violi F. Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: effect of ascorbic acid. Free Rad Biol Med 2007, 43:853-859. 10.1016/j.freeradbiomed.2007.06.002, 17664149.
26. Angelico F, Loffredo L, Pignatelli P, Augelletti T, Carnevale R, Pacella A, Albanese F, Mancini I, Di Santo S, Del Ben M, Violi F. Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Int Emerg Med 2012, 7:219-227.
27. Loffredo L, Martino F, Carnevale R, Pignatelli P, Catasca E, Perri L, Calabrese CM, Palumbo MM, Baratta F, Del Ben M, Angelico F, Violi F. Obesity and hypercholesterolemia are associated with NOX-2 generated oxidative stress and arterial dysfunction. J Pediatr 2012, 161:1004-1009. 10.1016/j.jpeds.2012.05.042, 22727869.
28. Del Ben M, Fabiani M, Loffredo L, Polimeni L, Carnevale R, Baratta F, Brunori M, Albanese F, Augelletti T, Violi F, Angelico F. Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulm Med 2012, 23(12):36.
29. World Health Organisation Definition diagnosis and classification of diabetes mellitus and its complications 1999, Geneva, Switzerland: World Health Organisation, Report of a WHO Consultation, World Health Organisation.
30. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765, American Heart Association; National Heart, Lung, and Blood Institute.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
32. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2010, 30:360-367. 10.1161/ATVBAHA.109.198622, 19965781.
33. Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exper Ther 1995, 275:94-100.
34. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasound findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007, 102:1-8.
35. Seki S, Kitata T, Yamada T, Sakaguchi H, Nakatami K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002, 37:56-62. 10.1016/S0168-8278(02)00073-9, 12076862.
36. Roest M, Voorbij HA, Van der Schouw YT, Peeters PH, Teerlink T, Scheffer PG. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J Clin Lipidol 2008, 2:298-303. 10.1016/j.jacl.2008.06.004, 21291746.
37. Feldstein AE, Anna Wieckowska A, Rocio Lopez A, Yao-Chang L, Nizar Zein N, Arthur McCullough J, Rocio Lopez A, Yao-Chang L, Nizar N, Arthur J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078. 10.1002/hep.23050, 2757511, 19585618.
38. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009, 51:1061-1067. 10.1016/j.jhep.2009.09.001, 19846234.